News
1h
Zacks.com on MSNPfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm ...
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $139.00.
In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued ...
BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...
In trading on Tuesday, shares of BioNTech SE (Symbol: BNTX) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $87.605 per share. By comparison ...
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $283,790, and 2 are calls, amounting to ...
5d
TipRanks on MSNBioNTech SE Announces Virtual Annual General Meeting for 2025BioNTech SE ( ($BNTX) ) has shared an update. On April 4, 2025, BioNTech SE announced the invitation to its Annual General Meeting scheduled for ...
Nevertheless, BNTX’s robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology. In my view, BioNTech's long-term value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results